• Jobs
  • Startups
  • Hire
LoginSign up
Organization banner, image 1 of 4
Organization banner, image 2 of 4
Organization banner, image 3 of 4
Organization banner, image 4 of 4

Role description

Your Desired Role

Ratio Therapeutics logoRatio Therapeutics
LocationBoston, MA
Posted1/18/2023
Other

Don't see a role that meets your qualifications but you are interested in working at Ratio Therapeutics?? Upload your resume and cover letter with more information about you!

About Ratio Therapeutics

Ratio Therapeutics is committed to improving and extending the lives of cancer patients without sacrificing their quality of life. We are a team of passionate scientists, engineers, and business professionals dedicated to advancing the field of targeted radioligand therapy to enable new therapies with higher cure rates and fewer side effects. To accomplish this, we utilize our proprietary TRILLIUM™ and MACROPA™ platforms:  TRILLIUM™ allows fine-tuning of radioligand pharmacokinetics thereby enhancing the therapeutic index, while MACROPA™ simplifies the manufacturing process for the alpha-emitting isotope, actinium-225. These enabling platform technologies have resulted in an emergent pipeline of novel therapeutic candidates. We are looking for talented, dedicated, and creative individuals eager to help us advance these technologies from discovery research through clinical development. Join us in our quest to become the leading innovator in radioligand therapy and improve the lives of cancer patients and their families.

Relevant archetypes

Apply on BambooHR
Save

Company info

Ratio Therapeutics logo

Ratio Therapeutics

The Partner of Choice for Next-Generation Radiopharmaceutical Precision Medicine

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.

Private companySeries C
Founded2021
HQBoston, United States
Size
Unlock human wisdom
ThesisTermsPrivacy
11–50 employees
IndustryBiotechnology Research
Funding
  • Series C · Jul 31, 2026
Investors
Catalio Capital ManagementDuquesne Capital ManagementSchusterman Family InvestmentsBristol-Myers SquibbEli Lilly

Claim ratiotx.com

Work at ratiotx.com? Sign in to claim this org and manage its profile.

© 2026 Saywise Inc.